Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
1.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K
Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
3.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.4K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial double-stranded RNA fuels pancreatic cancer growth via RIG-I/TLR3 inflammation.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small molecules.

Cell reports·2025
Same author

Androgen Receptors Promote Oxidative Phosphorylation and Resistance to Palmitate Lipotoxicity in ER-Mutant Breast Cancer.

Endocrinology·2025
Same author

Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity.

Cancer research·2025
Same author

eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small molecules.

bioRxiv : the preprint server for biology·2025
Same author

Kaposi's sarcoma-associated herpesvirus induces mitochondrial fission to evade host immune responses and promote viral production.

Nature microbiology·2025

Related Experiment Video

Updated: Mar 28, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.3K

Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy.

M Cecilia Caino1, Dario C Altieri2

  • 1Prostate Cancer Discovery and Development Program, Tumor Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, Pennsylvania.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 15, 2015
PubMed
Summary

Targeting mitochondrial metabolism is crucial for cancer therapy as it drives drug resistance. Inhibiting mitochondrial Hsp90 shows promise in preventing tumor adaptation and enhancing antitumor activity.

More Related Videos

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates
11:32

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates

Published on: August 6, 2021

3.1K
MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells
11:13

MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells

Published on: February 22, 2017

14.0K

Related Experiment Videos

Last Updated: Mar 28, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.3K
Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates
11:32

Analytical Determination of Mitochondrial Function of Excised Solid Tumor Homogenates

Published on: August 6, 2021

3.1K
MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells
11:13

MitoCeption: Transferring Isolated Human MSC Mitochondria to Glioblastoma Stem Cells

Published on: February 22, 2017

14.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Metabolic Pathways

Background:

  • Current PI3K/Akt/mTOR inhibitors paradoxically reactivate the targeted pathway.
  • Mitochondrial metabolism drives tumor adaptation, leading to drug resistance and metastasis in cancers like melanoma, glioblastoma, and prostate cancer.

Purpose of the Study:

  • To explore targeting mitochondrial metabolism for cancer therapy.
  • To investigate the role of mitochondrial chaperones in adaptive tumor responses.
  • To evaluate novel mitochondrial therapeutic strategies.

Main Methods:

  • Investigated PI3K antagonists and their effect on mitochondrial reprogramming.
  • Examined the role of mitochondrial Hsp90 family chaperones in apoptosis suppression and cell motility.
  • Assessed preclinical inhibitor gamitrinib targeting mitochondrial Hsp90.
  • Reviewed small-molecule inhibitors of mutant IDH (AG-120, AG-221) and ROS-elevating agents (ARQ 501, elesclomol).

Main Results:

  • Mitochondrial reprogramming enhances cancer cell survival, motility, and invasion.
  • Mitochondrial Hsp90 suppresses apoptosis and aids cell motility.
  • Gamitrinib prevents adaptive mitochondrial reprogramming and demonstrates potent antitumor activity.
  • IDH inhibitors show promise in AML; ROS-elevating agents have limited clinical success.

Conclusions:

  • Targeting mitochondrial bioenergetics is a promising strategy for cancer treatment.
  • Inhibiting mitochondrial Hsp90 offers a novel therapeutic approach to overcome drug resistance.
  • Further research into mitochondrial-targeted therapies is warranted.